T cell lymphomas are among the toughest blood cancers to treat. Immunotherapy, despite its success in many cancers, struggles ...
Readers will learn how veterinary oncologists stage and treat canine lymphoma using modern multi-agent chemotherapy and palliative care.
A two-vaccine immunotherapy targeting T-cell receptors and tumor-specific mutations improved tumor control and survival in preclinical models, offering a potential new strategy against ...
T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...
Imohgen Alo rang the bell at John Hunter Children's Hospital on Friday to mark the end of her cancer treatment. The NSW Lake ...
12d
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Lyell Immunopharma, Inc. ( LYEL) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM EST ...
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
NEW YORK – Lyell Immunopharma on Thursday started treating lymphoma patients on their second line of treatment in a Phase III trial comparing its CAR T-cell therapy rondecabtagene autoleucel ...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results